Jesse Diaz Correa, MD
Nephrology · Caguas, PRNPI 1609242288
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Merck at 27.0% of the total. Reporting peaked in 2024 at $1,743 and has fallen 57.5% since, to $741 in 2025.
Across 83 payments — averaging $61.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- AstraZeneca$778
- Boehringer Ingelheim$210
- Mallinckrodt Hospital Products Inc.$202
- Vifor Pharma, Inc.$195
- plus $993 from 14 others
What the payments were for
- Consulting fees$1,34026%
- Travel & lodging$1,17523%
- Food & beverage$2,41247%
- Education$1683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $1,377 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,340 |
| AstraZeneca(2 entities) | 32 | $778 |
| Boehringer Ingelheim | 7 | $210 |
| Mallinckrodt Hospital Products Inc. | 2 | $202 |
| Vifor Pharma, Inc. | 4 | $195 |
| Fresenius USA Marketing, Inc. | 1 | $154 |
| Amgen(2 entities) | 2 | $143 |
| Bayer Puerto Rico Inc. | 6 | $139 |
| Travere Therapeutics, Inc. | 1 | $124 |
| Bayer | 3 | $121 |
| OPKO Pharmaceuticals, LLC | 3 | $68 |
| La Jolla Pharmaceutical Company | 2 | $47 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| Novartis | 2 | $38 |
| Nxstage Medical, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Veloxis Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$227
- LIBERTY SELECT CYCLER$154
- NXSTAGE SYSTEM ONE$154
- KRYSTEXXA$125
- Filspari$124
- JARDIANCE$104
- ACTHAR$102
How this compares
$5,094 in reported general payments places this provider in the 85th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 132 | $81,330 |
| JardianceEmpagliflozin | 110 | $75,517 |
| LokelmaSodium Zirconium Cyclosilicate | 68 | $46,328 |
| Lanthanum Carbonate | 68 | $40,802 |
| GlyxambiEmpagliflozin/Linagliptin | 38 | $27,168 |
| Sevelamer Carbonate | 181 | $25,321 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 38 | $23,806 |
| OzempicSemaglutide | 15 | $14,734 |
| JanuviaSitagliptin Phosphate | 19 | $10,910 |
| Sodium Polystyrene Sulfonate | 28 | $3,454 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $1,670 |
| Losartan Potassium | 175 | $1,282 |
| Irbesartan | 58 | $1,069 |
| SynthroidLevothyroxine Sodium | 13 | $988 |
| Nifedipine ErNifedipine | 46 | $852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $778 | $127,658200 claims |
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr | $210 | $126,491186 claims |
| MerckJanuvia | $1,377 | $10,91019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Caguas
- Eugenia Galindo RamosCaguas$7K
- Enrique AcostaCaguas$4K
- Jacobo Loyola-TorresCaguas$3K
- Ricardo Calderon OrtizCaguas$3K
- Moises Ortiz VillalobosCaguas$3K
- Rafael Baquero AlvarezCaguas$3K
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.